Copyright: ©Author(s) 2026.
World J Gastrointest Surg. Mar 27, 2026; 18(3): 114569
Published online Mar 27, 2026. doi: 10.4240/wjgs.v18.i3.114569
Published online Mar 27, 2026. doi: 10.4240/wjgs.v18.i3.114569
Table 3 Comparative evaluation of treatment-emergent adverse events, n (%)
| Adverse reactions | Control group (n = 60) | Research group (n = 64) | χ2 | P value |
| Thrombocytopenia | 17 (28.33) | 10 (15.63) | 2.936 | 0.087 |
| Hemoglobin reduction | 11 (18.33) | 13 (20.31) | 0.078 | 0.780 |
| Nausea/vomiting | 15 (25.00) | 14 (21.88) | 0.169 | 0.681 |
| Myelosuppression | 12 (20.00) | 15 (23.44) | 0.215 | 0.643 |
- Citation: Shi JF, Xu H, Gao JF, Wu JB. Adjuvant irinotecan-apatinib therapy for recurrent/metastatic gastric cancer after surgery: A real-world evaluation. World J Gastrointest Surg 2026; 18(3): 114569
- URL: https://www.wjgnet.com/1948-9366/full/v18/i3/114569.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v18.i3.114569